Diphenylene iodonium, an inhibitor of free radical formation, inhibits platelet aggregation

Eur J Pharmacol. 1991 Jun 18;199(1):15-8. doi: 10.1016/0014-2999(91)90631-y.

Abstract

Diphenylene iodonium is an inhibitor of the enzyme NADPH-oxidase and prevents the generation of oxygen-derived free radicals in neutrophils (Cross and Jones, 1986). Here we show that diphenylene iodonium (0.25-2 microM) inhibited, according to the dose, thrombin-induced platelet-aggregation in human washed platelets and ADP-induced platelet aggregation in platelet-rich plasma. At the concentrations which inhibited platelet aggregation diphenylene iodonium did not alter platelet concentrations of cAMP or cGMP but enhanced the anti-platelet activity of iloprost, sodium nitroprusside or cultured endothelial cells. These findings highlight the importance of free radicals as platelet pro-aggregatory agents.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Diphosphate / pharmacology
  • Biphenyl Compounds / pharmacology*
  • Cyclic AMP / metabolism
  • Cyclic GMP / metabolism
  • Endothelium, Vascular / cytology
  • Free Radicals
  • Humans
  • Iloprost / pharmacology
  • In Vitro Techniques
  • Leukocytes / drug effects
  • Leukocytes / enzymology
  • NADH, NADPH Oxidoreductases / antagonists & inhibitors
  • Nitroprusside / pharmacology
  • Onium Compounds / pharmacology*
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors*
  • Thrombin / pharmacology

Substances

  • Biphenyl Compounds
  • Free Radicals
  • Onium Compounds
  • Platelet Aggregation Inhibitors
  • diphenyliodonium
  • Nitroprusside
  • Adenosine Diphosphate
  • Cyclic AMP
  • NADH, NADPH Oxidoreductases
  • Thrombin
  • Cyclic GMP
  • Iloprost